Merck & Co., Schering-Plough and their cholesterol joint venture – Merck/Schering-Plough Pharmaceuticals, have reached a civil settlement with a multistate group of attorneys general representing 35 states and
Cadence’s New Drug Application (NDA) for Acetavance (intravenous acetaminophen) has been accepted for filing by the FDA, and is designated for Priority Review. The drug will be used
Targacept has showed positive top-line results from a double blind, placebo controlled, flexible dose phase 2b clinical trial of TC-5214. It is to be used as an augmentation
Mentor Capital has announced that Quantum Immunologics (QI) is beginning its FDA-authorized breast cancer trial, the completion of the first clinical treatment injection. QI is currently sponsoring and
Data Monitoring Committees (DMCs), after predefined interim analyses, recommended that Paion should proceed with their phase IIa study, as well as phase Ib of CNS 7065 for anesthetic/sedative.
Taro has received patent covering its Ovide (malathion) lotion, 0.5% (patent no. US 7,560,445) from the US Patent and Trademark Office. The patent is for a highly pure
Saudi Basic Industries (Sabic) has commissioned unit Yansab 2290.SE, to start production from its petrochemical complex in Yanbu – as reported in Reuters. The launch was delayed for
The US Patent and Trademark Office has issued a patent to PolyMedix, relating its angiogenesis inhibitors. The patent number 7,553,876, entitled ‘Polycationic Compounds and Uses Thereof,’ relates to
EnVivo has completed phase Ib/IIa trial in Alzheimer’s disease patients with its nicotinic alpha-7 agonist EVP-6124. Subjects receiving EVP-6124 experienced improvement in cognition and EVP-6124 showed good tolerability
Pfizer has announced the results from two phase 1 safety studies. One of PF-04360365, a humanized anti-amyloid monoclonal antibody, and another of dimebon in combination with donepezil HCl
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.